Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Northwest Biotherapeutics

Sort by

Northwest Biotherapeutics: Thoughts on Why the Phase 3 Trial of DCVax-L is Ongoing (NWBO, BUY, $0.17)

Wednesday, September 13, 2017 · 10:46 am

Read More

Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)

Thursday, September 7, 2017 · 9:56 am

Read More

Northwest Biotehrpeutics: How Does DCVax-L Clinical Data Compare to the CAR-T Therapy Axi-Cel? (NWBO, $0.18, Buy)

Friday, August 25, 2017 · 10:28 am

Read More

Northwest Biotherapeutics: Why I Believe That the Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Patients Has a Very Good Chance for Success (NWBO, Buy, $0.17)

Friday, July 7, 2017 · 11:18 am

Read More

Northwest Biotherapeutics: Is There Any Chance for DCVax-L to be Successful in the Phase 3 Trial? (NWBO, Buy, $0.24)

Monday, March 27, 2017 · 3:45 pm

Read More

Northwest Biotherapeutics and Agenus: What Are The Implications for These Companies in the Aftermath of Two Recent Cancer Vaccine Trial Failures? (NWBO, $0.38, Buy) (AGEN, $3.99, Buy)

Monday, February 27, 2017 · 12:10 pm

Read More

Northwest Biotherapeutics: 8-K Document Released Today Provides New and Very Interesting Data on Patients Treated with DCVax-L. (NWBO, Buy, $0.48)

Wednesday, February 8, 2017 · 4:06 pm

Read More

Northwest Biotherapeutics: Partial Clinical Hold on Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma is Lifted (NWBO, Buy, $0.45)

Tuesday, February 7, 2017 · 3:06 pm

Read More

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Tuesday, January 3, 2017 · 10:18 am

Read More

Northwest Biotherapeutics: DCVax-L Viewed Through the Eyes of Dr. Linda Liau, Lead Investigator on the Phase 3 Trial of DCVax-L (NWBO, $0.35, Buy)

Wednesday, December 21, 2016 · 4:46 pm

Read More

Northwest Biotherapeutics: Phase 2 Trial in Colorectal Cancer with Liver Metastases Announced (NWBO, Buy, $0.55)

Thursday, November 17, 2016 · 9:57 am

Read More

Northwest Biotherapeutics: Recent Data Update on Phase 1/2 Trial of DCVax Direct is Encouraging (NWBO, Speculative Buy, $0.43)

Sunday, October 9, 2016 · 9:46 am

Read More

Northwest Biotherapeutics: My Hypothesis as to Why the Company Has Been Silent on Its Clinical Trial Programs and Why DCVax-L Might Succeed in its Phase 3 Trial (NWBO, Speculative Buy, $0.34)

Thursday, September 8, 2016 · 3:25 pm

Read More

Northwest Biotherapeutics: Going Over My Thoughts (NWBO, $0.62)

Monday, June 20, 2016 · 9:35 am

Read More

Northwest Biotherapeutics: The Company Provides an Operations Update (NWBO, $1.23)

Thursday, May 5, 2016 · 9:29 am

Read More

Northwest Biotherapeutics: A Comprehensive Evaluation of Its Lead Product DCVax-L (NWBO, $1.50)

Tuesday, March 22, 2016 · 1:32 pm

Read More

Northwest Biotherapeutics: Why the Failure of Celldex’s Rintega in Newly Diagnosed Glioblastoma Probably Has No Implications for the DCVax-L Trial

Friday, March 11, 2016 · 8:35 am

Read More

Northwest Biotherapeutics: Seeking Alpha Publishes Latest in a String of Attack Articles Authored by Short Sellers (NWBO, $4.92)

Thursday, October 29, 2015 · 10:24 am

Read More

Northwest Biotherapeutics: New Financing from Woodford was Much Needed (NWBO, $5.44)

Wednesday, October 21, 2015 · 2:27 pm

Read More

Northwest: Analysis of a Coordinated Short Selling Attack Against the Stock (NWBO, $4.69)

Tuesday, October 20, 2015 · 12:36 pm

Read More

Northwest Biotherapeutics: My Thoughts on the New Data from the Phase 1/2 Trial of DCVax Direct (NWBO, Buy, $6.91)

Monday, September 28, 2015 · 9:00 am

Read More

Northwest Biotherapeutics: Thoughts on Suspension of Screening of New Patients in the Phase 3 DCVax-L Trial

Tuesday, September 8, 2015 · 8:25 am

Read More

Observations from ASCO on Immuno-oncology with a Focus on Northwest Biotherapeutics’ (NWBO, Buy, $9.43) DC-Vax-Direct© and the Checkpoint Inhibitors of Bristol-Myers Squibb and Merck

Monday, June 8, 2015 · 8:35 am

Read More

Northwest Biotherapeutics: FDA Panel Recommendation to Approve Amgen’s Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax Direct. (NWBO, $7.86, Buy)

Friday, May 1, 2015 · 11:42 am

Read More

CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?

Wednesday, April 29, 2015 · 8:57 am

Read More

Northwest Biotherapeutics: Comments on Two AACR Posters (NWBO, $8.62, Buy)

Wednesday, April 15, 2015 · 1:18 pm

Read More

Northwest Biotherapeutics: The $40 Million Woodford Financing is A Major Positive (NWBO, Buy, $7.76)

Friday, April 3, 2015 · 2:37 pm

Read More

Northwest Biotherapeutics: Still Another Rebuttal to a Feuerstein Attack Is Called For

Friday, April 3, 2015 · 8:33 am

Read More

Northwest Biotherapeutics: Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Multiforme (NWBO, Buy, $7.29)

Friday, March 27, 2015 · 9:27 am

Read More

Northwest Biotherapeutics: How Much Will It Cost to Manufacture DCVax-L (NWBO, Buy, $7.26)

Thursday, March 5, 2015 · 10:02 am

Read More

The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology Landscape (NWBO, Buy, $6.19)

Tuesday, February 3, 2015 · 9:01 am

Read More

Notes from Linda Powers Presentation in San Francisco, January 12, 2015 (NWBO, Buy, $6.00)

Tuesday, January 13, 2015 · 8:53 am

Read More

Northwest Biotherapeutics: Putting Recent Clinical Data on DCVax Direct in Perspective (NWBO, Buy, $5.37)

Friday, November 28, 2014 · 12:31 pm

Read More

Northwest Biotherapeutics: Exciting News on Potential for Early Patient Access for DCVax-L in the UK

Wednesday, September 17, 2014 · 1:25 pm

Read More

Northwest Biotherapeutics: National Geographic Special Features DCVax Direct Treatment of Stage 4 Pancreatic Cancer Patient (NWBO, Buy, $5.90)

Monday, September 8, 2014 · 9:47 am

Read More

Northwest Biotherapeutics: Independent Chairman of the DMC Committee for DCVax-L Phase 3 Trial Chastises Adam Feuerstein for Inaccurate Articles (NWBO, Buy, $6.43)

Wednesday, August 13, 2014 · 12:00 pm

Read More

CREW Alleges That Adam Feuerstein is Involved in Stock Manipulation Scheme in Regard to Northwest Biotherapeutics

Wednesday, July 30, 2014 · 10:18 am

Read More

Northwest Biotherapeutics: Market Research Firm Evaluate Pharma Projects 2020 Worldwide Sales of $2.0 billion for DCVax-L (NWBO, Buy, $5.92)

Thursday, July 17, 2014 · 11:35 am

Read More

Northwest Biotherapeutics: The Investment Tide May be Turning Positive (NWBO, Buy, $6.41, free content)

Thursday, June 12, 2014 · 9:02 am

Read More

Linda Powers, CEO of Northwest Biotherapeutics, Attacks and Debunks the Weak Bear Case in a Presentation on March 27

Friday, March 28, 2014 · 7:15 am

Read More

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Friday, February 14, 2014 · 4:28 pm

Read More

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

Wednesday, January 22, 2014 · 3:48 pm

Read More

Northwest Biotherapeutics: An Analysis of Its Transforming Balance Sheet Restructuring (NWBO, $4.14)

Monday, December 9, 2013 · 9:42 am

Read More

Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward and Starting DC Vax Direct Trials (NWBO, $3.63)

Tuesday, May 7, 2013 · 12:44 pm

Read More

Northwest Biotherapeutics: My Rationale for Having a Buy Recommendation (NWBO; $3.29)

Monday, February 25, 2013 · 11:47 am

Read More

Northwest Biotherapeutics: A Critique of Adam Feuerstein of TheStreet's Recent Analysis (NWBO, $3.50)

Tuesday, February 19, 2013 · 9:52 am

Read More

Northwest Biotherapeutics: Transformed from an Ugly Duckling Bulletin Board Company to a Promising NASDAQ Company (NWBO, $3.20)

Monday, January 14, 2013 · 12:55 pm

Read More

Northwest Biotherapeutics and ImmunoCellular Therapeutics Can Both Be Winners with their Cancer Vaccines (NWBOD, $5.50)

Friday, September 28, 2012 · 10:10 am

Read More

Northwest Biotherapeutics’ DCVax Cancer Vaccines May Be a Game Changer In Cancer Therapy (NWBO, $0.22)

Thursday, July 19, 2012 · 10:54 am

Read More

The Rationale Behind Dendritic Cell-Based Cancer Vaccines and How They are Manufactured (NWBO.OB, $0.22)

Thursday, April 26, 2012 · 6:24 am

Read More

There are 50 reports on file.

« Back to Company Reports Index